Skip to main content
JAGX logo

JAGX · Jaguar Health, Inc. · Webcasts, Transcripts & Audio

Track JAGX — free
$2.63 -0.19 (-6.74%) At close · Oct 20
Market Cap
$1.81M
Shares
689,107
Volume · Oct 20 266.67K Avg daily vol (3 sessions) 557.76K

Jaguar Health, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Jaguar Health, Inc. (JAGX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q2
2026-08-19
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Transcript
Confident tone Near-term clinical and regulatory catalysts FuturePac out-license of Mytesi/Canalevia Prescription product revenue decline
Revenue
$1.23M
▼ 58.9% YoY
Diluted EPS
$-117.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-26
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Transcript
Confident tone Intestinal failure / MVID lead indication Regulatory pathway and breakthrough designation Business development / partnership strategy
Revenue
$20.27M
▲ 815.6% YoY
Diluted EPS
$-102.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript
Confident tone Clinical catalysts in MVID/SBS Animal Health / Canalevia partnership Oncology label expansion (CTD/metastatic breast cancer)
Revenue
$2.98M
▲ 9.5% YoY
Diluted EPS
$-2692.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript
Positive tone Rare disease program (MVID / SBS-IF) Crofelemer / Mytesi prescription sales Business development and partnerships
Revenue
$2.21M
▼ 5.8% YoY
Diluted EPS
$-4383.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call
Revenue
$3.51M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
Confident tone Crofelemer pipeline and orphan indications FDA engagement and regulatory pathway OnTarget Phase III trial results and breast cancer subgroup
Revenue
$3.11M
▲ 10.5% YoY
Diluted EPS
$-6901.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript
Positive tone Crofelemer clinical pipeline Rare/orphan disease indications (MVID/SBS) Gelclair commercial launch
Revenue
$2.72M
Diluted EPS
$-698.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Call Transcript
Positive tone Pipeline and business focus Gelclair / oral mucositis expansion Financial losses / operating loss
Revenue
$2.35M
Diluted EPS
$-22869.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript
Revenue
$2.81M
Diluted EPS
$-147656.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript
Diluted EPS
$-271359.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Jaguar Health, Inc. (JAGX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-941062.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Jaguar Health, Inc. (JAGX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Jaguar Health, Inc. (JAGX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-3476812.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Jaguar Health, Inc. (JAGX) Q2 2022 Earnings Call Transcript
Diluted EPS
$-3453187.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Jaguar Health, Inc. (JAGX) Q1 2022 Earnings Call Transcript
Diluted EPS
$-9095625.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-11
Jaguar Health, Inc. (JAGX) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-18
Jaguar Health, Inc. (JAGX) Q3 2021 Earnings Call
Diluted EPS
$-7973437.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Jaguar Health, Inc. (JAGX) Q1 2021 Earnings Call
Diluted EPS
$-8268750.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q3
2020-11-16
Jaguar Health, Inc. (JAGX) Q3 2020 Earnings Call Transcript
Revenue
$2.77M
▲ 185% YoY
Diluted EPS
$-18309375.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Jaguar Health, Inc. (JAGX) Q2 2020 Earnings Call Transcript
Revenue
$3.17M
▲ 85.6% YoY
Diluted EPS
$-38981250.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-06
Jaguar Health, Inc. (JAGX) Q1 2020 Earnings Call Transcript
Revenue
$869,000
▼ 45.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1585608 CUSIP 47010C854 13F (30d) 1 filings 1 filers Visit website Investor relations